# Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

> **NCT03682055** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 14 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** VK-2019

## Key facts

- **NCT ID:** NCT03682055
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-04
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-08-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2023-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03682055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03682055, "Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03682055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*